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Abstract
Background: Neurologic Post Treatment Lyme disease (nPTLS) and Chronic Fatigue (CFS) are syndromes of unknown
etiology. They share features of fatigue and cognitive dysfunction, making it difficult to differentiate them. Unresolved is
whether nPTLS is a subset of CFS.
Methods and Principal Findings: Pooled cerebrospinal fluid (CSF) samples from nPTLS patients, CFS patients, and healthy
volunteers were comprehensively analyzed using high-resolution mass spectrometry (MS), coupled with immunoaffinity
depletion methods to reduce protein-masking by abundant proteins. Individual patient and healthy control CSF samples
were analyzed directly employing a MS-based label-free quantitative proteomics approach. We found that both groups, and
individuals within the groups, could be distinguished from each other and normals based on their specific CSF proteins
(p,0.01). CFS (n=43) had 2,783 non-redundant proteins, nPTLS (n=25) contained 2,768 proteins, and healthy normals had
2,630 proteins. Preliminary pathway analysis demonstrated that the data could be useful for hypothesis generation on the
pathogenetic mechanisms underlying these two related syndromes.
Conclusions: nPTLS and CFS have distinguishing CSF protein complements. Each condition has a number of CSF proteins
that can be useful in providing candidates for future validation studies and insights on the respective mechanisms of
pathogenesis. Distinguishing nPTLS and CFS permits more focused study of each condition, and can lead to novel
diagnostics and therapeutic interventions.
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Introduction
Prime objectives in studying neurologic and psychiatric
disorders are to develop discriminating markers and generate
data that can provide insight into disease pathogenesis. This can
lead to novel treatment strategies. Chronic Fatigue Syndrome
(CFS) and Lyme disease, particularly Neurologic Post Treatment
Lyme disease syndrome (nPTLS), represent two conditions that
share common symptoms of fatigue and cognitive dysfunction [1–
7]. Despite extensive research CFS and nPTLS remain medically
unexplained. There are no biological markers to distinguish these
syndromes, creating diagnostic dilemmas and impeding research
into understanding each individual syndrome.
Cerebrospinal fluid (CSF) is an ideal body fluid to examine for
signature protein profiles informative for diagnosis or etiology of
central nervous system (CNS)-related symptoms and dysfunction.
PLoS ONE | www.plosone.org 1 February 2011 | Volume 6 | Issue 2 | e17287Not only is the CSF an accessible liquid extension of the brain, but
recent data suggests CSF may provide more relevant data than
brain parenchyma itself in certain neurologic diseases [8]. Specific
abnormalities found in CSF relating to CFS and nPTLS would
suggest CNS involvement, and could facilitate their mechanistic
understanding.
Liquid chromatography coupled to mass spectrometry (LC-
MS) is becoming the method of choice for examining complex
biological specimens, that contain hundreds to thousands of
proteins [9], such as CSF [10]. This is particularly the case in the
initial discovery phase. This discovery phase may be viewed as
casting a wide net to maximize identification of as many proteins
as possible in a sample. This initial list of identified proteins has
value by itself for qualitative or semi-quantitative comparisons
between diseases. Recent studies demonstrated the reliability and
reproducibility of LC-MS results, with different mass spectrom-
eters across different laboratories, when performed by experi-
enced individuals [9,11]. In a discovery phase investigation, the
MS technique is unbiased and does not require prior knowledge
of what proteins may be in a sample. This is in contrast to
subsequent validation studies where targeted approaches are used
and which do require knowledge of target proteins. In searching
for a disease biomarker, the discovery phase should provide a list
of proteins and serve as a precursor phase for targeted approa-
ches. These subsequent targeted approaches, whether they use
other MS techniques or are immuno-based, are designed to
validate the use of the biomarker protein(s) to distinguish one
disease from another.
In practice tailored strategies are often needed to achieve a
balance between ideal and real world constraints – especially
where sample volumes and numbers are limited such as with CSF.
In an ideal situation it is desirable to have numerous samples from
individuals with a particular disease. It is further desirable to have
sufficient total protein content in each sample so that a variety of
protein separation and fractionation methods can be used prior to
MS analysis. This will minimize abundant proteins from masking
the detection of less abundant ones, and will permit full qualitative
and quantitative analyses. Limited sample numbers and quantities
do not preclude employment of tailored strategies to get
meaningful results. It should be remembered that in the example
of a biomarker search, the protein(s) will be confirmed or dismissed
in future targeted validation studies, but failure to identify them in
the broad discovery list would preclude them from examination
for validation.
Until recently, technical hurdles impeded the use of CSF to
distinguish conditions such as CFS and nPTLS. Advances in sample
preparation, separations and MS platform capabilities enabled us
to recently establish a comprehensive reference normal CSF
proteome [10]. This provides the basis for comparative proteome
analyses with other diseases, which should provide greater insight
into their underlying pathogenesis.
To address the possibility that CFS and nPTLS could be dis-
tinguished from one another and healthy subjects, we searched
for distinguishing protein marker profiles by applying our
advanced proteomics strategy [10] to characterize the CSF
proteomes from well described CFS and nPTLS patients (detailed
in Methods). We performed comparative whole CSF proteome
analyses between CFS, nPTLS, and healthy normal controls, and
complemented these findings with label-free quantitative analysis
of individual subject samples. In addition, we performed a
preliminary pathway analysis [12] using these data, to examine
the feasibility of this type of tool for future investigations to
probe for clues to the pathogenetic mechanisms behind these
diseases.
Materials and Methods
Ethics Statement
Approval for the conduct of this study was obtained from the
Institutional Review Board of New Jersey Medical School and the
Institutional Review Board of Pacific Northwest National Laboratory
(Exempt status and consent not required, using previouslybanked de-
identified samples in accordance with federal regulations).
Overview and Rationale
We performed analysis of pooled CSF samples allowing for a
broad and deep view as well as qualitative comparison of each
disease-related and control CSF proteome. To determine if these
two syndromes could be quantitatively differentiated we per-
formed a label-free quantitative analysis of protein abundances for
individual subject CSF samples. Pooling samples provided
sufficient protein mass for effective downstream proteomics
analysis following immunoaffinity depletion of the 14 most
abundant proteins present (representing approximately 95% of
the total protein mass in CSF), reducing the dynamic range of
protein concentrations present in CSF, where proteins with
highest concentrations mask proteins at lower concentrations from
detection. Coupling immunoaffinity depletion with strong cation
exchange (SCX) fractionation further reduces sample complexity,
and allowed for the in-depth analysis of the CSF proteomes. These
comprehensive CSF proteomics datasets were then used to create
an accurate mass and time (AMT) tag database for subsequent
label-free quantitative analysis of individual subject CSF samples.
Due to the limit in sample volume, the CSF samples used in
individual LC-MS analyses were not immunoaffinity depleted and
fractionated, and therefore had much lower proteome coverage
compared to the pooled samples. Nevertheless, the label-free
quantitative analysis of single subject samples provided a means for
statistical evaluation of the quantified protein abundances for
many subjects suffering from CFS and nPTLS as well as normal
healthy volunteers. Together these analyses represent the disco-
very phase of our studies on CFS and nPTLS, generating targets for
follow up verification and validation in the later stages of the
biomarker discovery workflow [13].
Cerebrospinal Fluid (CSF) specimens
CFS Subjects. Both pooled and individuals CSF samples
were analyzed. Equal aliquots from individual CSF samples were
pooled to provide sufficient volume for extensive fractionation and
two-dimensional LC coupled to tandem MS (2D-LC-MS/MS)
analysis with immunoaffinity depletion from 30 women and 13
men (n=43) who fulfilled the 1994 case definition for CFS [1]. All
subjects were 18–54 years old (median =43) and underwent a
careful history and physical examination by an expert experienced
in evaluating patients with medically unexplained fatigue and
pain. Patients had blood tests to rule out common causes of severe
fatigue such as anemia, liver disease, hypothyroidism, systemic
lupus erythematosus, and Lyme disease [14]. All subjects then
underwent a psychiatric diagnostic interview designed to identify
major psychiatric diagnoses for exclusion in this study. Eleven of
the patients were not taking medicines. Subjects then underwent
lumbar puncture. CSF was sent to the laboratory for white blood
cell (wbc) count and total protein [10]. A majority of CFS patients
had normal CSF protein and cell counts (protein less than 45 mg/
dl and wbc less than or equal to 5/mm
3). Ten of the patients had
increased protein values ranging from 46–93 mg/dl (with a
median of 59 mg/dl) and 3 patients had minimally elevated wbc
counts of 6, 7, and 9 respectively. Individual CSF samples from 14
of the 43 CFS subjects (aged 33–48 years with a median age of 43
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analysis (i.e., no MS/MS was performed) without immunoaffinity
depletion. Twelve of the 14 patients had normal CSF protein
levels and all had normal cell counts. All subjects provided written
informed consent approved by the Institutional Review Board.
nPTLS Subjects. Both pooled and individuals CSF samples
were analyzed. Equal aliquots from individual CSF samples
were pooled to provide sufficient volume for extensive frac-
tionation and 2D-LC-MS/MS analysis with immunoaffinity
depletion from 15 females and 10 males (n=25) with nPTLS.
All were documented to have had prior Lyme disease which
met CDC surveillance case definition criteria [15], persistent
neurologic features, including cognitive impairment and
fatigue, despite appropriate antibiotic treatment [16,17]. Sub-
jects were 17–64 years old (median =48). All were seropositive
for antibodies to B. burgdorferi (the etiologic agent of Lyme
disease). Patients, enrolled in an NIH funded study, met the
following criteria [17]: (1) current positive IgG Western blot
using CDC surveillance criteria assessed using a single
reference laboratory (University Hospital of Stony Brook); (2)
treatment for Lyme disease with at least 3 weeks of intravenous
ceftriaxone or cefotaxime that was completed at least 4 months
before study entry; and (3) objective evidence of memory
impairment as documented by the Wechsler Memory Scale-III
compared to age-, sex-and education-adjusted population
norms. nPTLS subjects were excluded if history or testing
revealed a medical condition that could cause cognitive
impairment or confound neuropsychological assessment (e.g.,
neurological disease, autoimmune disease, unstable thyroid
disease, learning disability, substance abuse, B12 deficiency).
Patients with cephalosporin allergy or a history of significant
psychiatric disorder prior to onset of Lyme disease were also
excluded. All patients had a comprehensive battery of neur-
ocognitive testing and a full-physical exam with detailed
rheumatologic and neurologic assessments. nPTLS patients
then had a lumbar puncture and CSF was evaluated for cell
count, total protein, glucose, total gammaglobulin, oligoclonal
bands and evidence of B. burgdorferi (ELISA, Bb DNA by PCR,
and culture using BSKII medium). None had evidence of
another active tick-borne disease. A majority of nPTLS patients
included in the pooled sample had normal CSF protein and
cell counts (protein less than 45 mg/dl and wbc less than or
equal to 5/mm
3), except for 3 patients who had elevated
protein values of 58, 69, and 71 mg/dl respectively and 1
patient with elevated wbc count of 6. Individual CSF samples
from a group of 14 of the 25 nPTLS subjects (aged 25–58 years
with a median age of 48 years, 6 female and 8 male) were also
used in direct LC-MS analysis without immunoaffinity
depletion. Two of the 14 patients had increased CSF protein
levels of 69 and 71 mg/dl and 1 had a slightly elevated wbc of
6. All subjects provided written informed consent approved by
the Institutional Review Board.
Normal Controls. We used the 2D-LC-MS/MS data
obtained previously from pooled CSF of 11 healthy control
subjects [10]. Briefly, there were 8 women and 3 men, aged 24–55
years with a median age of 28 years. Individual CSF samples from
another set of 10 healthy volunteers, age 37–44 years (median =
40) and 5 women and 5 men, were analyzed by LC-MS analysis
without immunoaffinity depletion.
Immunoaffinity depletion of 14 high abundance CSF
proteins
We had previously shown that this technique could increase our
protein identification yield by 70% [10]. Pooled CSF samples from
CFS or nPTLS patients (total volume of 18 mL each), were
fractionated using a 12.7679.0 mm SepproH IgY14 LC10 affinity
LC column (Sigma, St Louis, MO) as previously described [18].
Pooling was done to compensate for lack of sufficient volume (and
consequent protein content) available for immunoaffinity deple-
tion of individual patient samples. Both the flow-through (lower
abundance proteins) and bound fractions from both pooled CSF
samples were collected and processed identically until LC-MS/MS
analysis. These analyses resulted in an in-depth characterization of
the CSF proteome and the combined results of abundant protein
and less abundant protein fractions allowed the creation of an
AMT tag database [19] for high-throughput analysis of a larger
number of individual subject samples using LC-MS.
Protein digestion
CSF proteins (from the immunoaffinity depletion processed
pooled samples and the individual samples without immunoaffi-
nity depletion processing) were digested with trypsin and cleaned
up with SPE C18 columns as previously described [10]. Final
peptide concentration was determined by BCA assay (Pierce,
Rockford, IL). All tryptic digests were snap frozen in liquid
nitrogen and stored at 280uC until further processing and
analysis.
Strong cation exchange (SCX) fractionation
A total of 300 mg of tryptic peptides from both the IgY14 bound
and flow-through fractions from the pooled CFS and nPTLS CSF
samples were fractionated by SCX chromatography as described
[20]. Thirty SCX fractions were collected for each sample and
20% of each fraction was injected for reversed-phase LC-MS/MS
analysis.
Reversed-phase capillary LC-MS/MS for CSF pooled
fraction analysis
SCX fractions of the IgY14 bound fraction samples were
analyzed on an LTQ (ThermoFisher, San Jose, CA) linear ion
trap, and SCX fractions of the IgY14 flow-through fraction
samples were analyzed on an LTQ-Orbitrap Velos (Thermo-
Fisher) instrument, operated in data-dependent mode with the
same LC conditions as previously described [10].
Reversed-phase capillary LC-MS for label-free
quantification of unfractionated CSF samples
For label-free quantification analyzing unfractionated CSF
samples (individual patient samples with insufficient volume
(protein content) for immunoaffinity depletion and SCX fraction-
ation), the LTQ-Orbitrap Velos mass spectrometer was operated
in the data-dependent mode with full scan MS spectra (m/z 400–
2000) acquired in the LTQ-Orbitrap Velos with resolution of
60,000 at m/z 400 (accumulation target: 1,000,000). MS/MS data
acquired here were not used for the quantitative analysis.
Data analysis
The LTQ raw data from the pooled samples was extracted
using Extract_MSn (version 3.0; ThermoFisher) and analyzed with
the SEQUEST algorithm (V27 revision 12; ThermoFisher)
searching the MS/MS data against the human IPI database
(Version 3.40). Mass tolerances of 3 Daltons for precursor ions and
1 Dalton for fragment ions without an enzyme defined, as well as
static carboxyamidomethylation of cysteine and dynamic oxida-
tion of methionine were used for the database search. The LTQ-
Orbitrap Velos MS/MS data were first processed by in-house
software DeconMSn [21] accurately determining the monoisoto-
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search against the IPI database in the same fashion as described
above, with the exception that a 0.1-Dalton mass tolerance for
precursor ions and 1-Dalton mass tolerance for fragment ions were
used. Data filtering criteria based on the cross correlation score
(Xcorr) and delta correlation (DCn) values along with tryptic
cleavage and charge states were developed using the decoy
database approach and applied for filtering the raw data to limit
false positive identifications to ,1% at the peptide level [22–24].
For the LTQ-Orbitrap Velos data, the distribution of mass
deviation (from the theoretical masses) was first determined as
having a standard deviation (s) of 2.05 part per million (ppm), and
a mass error of smaller than 3s was used in combination with
Xcorr and DCn to determine the filtering criteria that resulted in
,1% false positive peptide identifications.
The AMTtagstrategy [19] was usedfor label-freequantificationof
MS features observed in the LTQ-Orbitrap Velos analysis of the
individual CSF samples from normal, CFS and nPTLS conditions.
The filtered MS/MS peptide identifications obtained from the 2D-
LC-MS/MS analyses of all pooled CSF samples were included in an
AMT tag databasewith their theoretical mass and normalized elution
time (NET; from 0 to 1) recorded. LC-MS datasets were then
analyzed by in-house software VIPER [25] that detects features in
mass–NET space and assigned them to peptides in the AMT tag
database [26]. The data was further filtered by requiring that all
peptides mustbe detected in at least 30% of the datasets in each of the
three conditions. The false discoveryrate of the AMT tag analysis was
estimated using an 11-Da shift strategy as previously described [27].
A false positive rate of ,4% was estimated for each of the LC-MS
data sets. The resulting lists of peptides from 2D-LC-MS/MS or
direct LC-MS analysis were further processed by ProteinProphet
software [28] to remove redundancy in protein identification.
Data normalization and quantification of the changes in protein
abundance between the normal, CFS and nPTLS CSF samples
were performed and visualized using in-house software DAnTE
[29]. Briefly, peptide intensities from the LC-MS analyses of the
individual samples (volume limited) were log2 transformed and
normalized using a mean central tendency procedure. Peptide
abundances from the individual samples were then ‘‘rolled up’’ to
the protein level employing the R-rollup method (based on trends
at peptide level) implemented in DAnTE. ANOVA, principal
component analysis (PCA) and clustering analyses were also
performed using DAnTE.
Pathway Analysis of the data was performed with Ingenuity
Pathways Analysis (Ingenuity Systems, www.ingenuity.com).
Canonical pathway analysis identified the pathways from the
Ingenuity Pathways Analysis library of canonical pathways that
were most significant to the CFS and nPTLS proteins identified.
The significance of the associations were assessed with the Fisher’s
exact test.
Results
We first performed pooled sample analysis, then individual
sample analysis, and then pathway analysis using the observed
proteins. These analyses represent a discovery phase of our studies
on CFS and nPTLS, generating targets which can be followed up in
future verification and validation stages studies [13].
Proteomic analysis of pooled CSF samples
In the pooled analysis, we examined individual sets of CSF
samples from CFS patients (n=43) and nPTLS patients (n=25),
respectively. We used the proteomic strategy described in Methods
to assure that the maximum number of proteins would be
analyzed and the more abundant proteins did not obscure the less
abundant ones having biomarker potential. The bound fraction
of abundant proteins from the immunoaffinity depleted flow
through fraction was analyzed separately and included in the
subsequent analysis. Combining immunoaffinity-based partition-
ing, SCX fractionation and LC-MS/MS, we identified approxi-
mately 30,000 peptides for each pooled sample corresponding to
2,783 nonredundant proteins in CFS patient samples and 2,768
proteins in nPTLS patient samples, compared to the 2,630 proteins
present in the CSF of healthy normal control subjects. These can
be graphically seen in Figure 1 which shows the number of
proteins identified solely in each group, and shared or not shared
between the groups (see Table S1). Figure 1 also shows that the
nPTLS and CFS groups shared significantly more proteins (n=305)
than each disease group shared with healthy controls (n’s=135
and 166, respectively). (Note that, as with any assay, when we
indicate that a protein was ‘‘not found’’ or ‘‘not identified’’ that is
defined as within the limits of detection).
Proteomic analysis of individual CSF samples
Quantitative analyses were performed on individual CSF
samples from 14 CFS patients and 14 nPTLS patients. They were
Figure 1. Characterization of the proteome from pooled and
individual CSF samples. A) Venn diagram of the qualitative
distribution of proteins identified in the pooled, immunodepleted,
and fractionated cerebrospinal fluid (CSF) from normal healthy control
subjects, Chronic Fatigue Syndrome (CFS), and Neurologic Post
Treatment Lyme Syndrome (nPTLS). The numbers of proteins for each
of these three categories separately is shown outside the circles below
the category (2,630 for true normal controls, 2,783 for CFS, and 2,768 for
nPTLS). The subsets of intersections between these categories are
shown within the circles. There were 1) 738 proteins that were
identified in CFS, but not in either healthy normal controls or nPTLS;2 )
1,582 proteins that were not identified in CFS, but were in either nPTLS
disease or healthy normal controls; 3) 692 proteins that were identified
in the nPTLS patients, but not in healthy normal controls or CFS; and 4)
1,597 proteins that were not identified in nPTLS, but were identified in
either healthy normal controls or CFS. This figure also shows that the
nPTLS and CFS groups shared significantly more proteins (n=305) than
each disease group shared with controls (n’s=135 and 166). The
specific lists of these subsets are presented in additional Table S1.
doi:10.1371/journal.pone.0017287.g001
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random) to provide insights on the variation among individuals
within and between different groups. Limited volumes of the
individual samples reduced the sample preparation options (i.e.,
immunoaffinity depletion and SCX fractionation), and hence
resulted in less depth of proteome coverage than possible with the
pooled samples, where approximately 20 ml were available for
depletion and fractionation. Nevertheless, we identified 4,522
peptides across all individual samples, representative of 474 non-
redundant proteins identified and quantified in the individual
sample analysis (Table S2).
Unsupervised hierarchical clustering and PCA were employed to
determine if the observed quantitative differences in protein abun-
dances were sufficient to distinguish these two patient groups (this was
de facto blinded – as samples were run in a random order and uncoded
as to disease group afterwards). The proteins considered in the
unsupervised hierarchical clustering analysis were quantified in
individual samples and found to be significantly different in abundance
by analysis of variance (ANOVA p # 0.01, Table S3); while PCA
analysis considered all proteins quantified in each individual sample.
The CSF proteome of the two disease states were markedly different
from each other (Fig. 2A and B). Individual patients also showed
consistent patterns of protein abundances discriminating CFS from
nPTLS (Fig. 2A). These results demonstrated that it is unlikely that any
single subject’s CSF sample in the pooled analysis contributed
disproportionately to the differential proteome distributions observed
between the disease groups. Moreover, the individual analyses also
highlighted the potential for diagnostic marker confirmation upon
extension to larger sample sets in validation studies.
Illustrative pathway analyses of protein results from CSF
samples
We utilized pathway analysis as an exploratory tool to assess the
value of our data, beyond distinguishing the two syndromes from
each other, to see if the data was amenable to analysis that would
help generate hypotheses of pathogenesis. We chose representative
pathways to analyze for illustration based in part on their
quantitative ranking (Table S4) and in part by the potential
relevance of the pathway involved. Even this limited investigation
demonstrated that there is a wealth of proteome information that
can be leveraged for hypotheses generation.
Example of proteins in common and elevated in
abundance in the two disease conditions, compared to
normal, but at different levels. An illustration, where the
same proteins are elevated in abundance in both conditions, but at
different magnitudes, is provided by inspection of proteins in the
complement system. This is of interest because both syndromes
may be triggered by infections (nPTLS in all cases by B. burgdorferi;
many CFS cases by one or more microbes yet to be identified). We
found that the complement cascade related proteins were
identified and significantly enriched in both CFS and nPTLS
pooled CSF proteomes by the Fisher Exact test (p=0.005)
implemented in Ingenuity Pathways Analysis (Figure S1A). In
individual patient samples analyzed, we identified and quantified 4
components (C1S, C4B, C1QB, C1QC) which are seen with
activation of the complement cascade and which were
differentially increased in abundance consistently across the
nPTLS patients compared to CFS (Figure S1B and C). This
represents the type of data that can be useful in the formulation of
pathogenetic hypotheses because the role of complement in these
disorders is under-explored.
Example of proteins solely identified in one
condition. Analysis of the highly fractionated pooled patient
samples led to the identification of proteins solely identified in each
of the disease states. To investigate if these disease specific proteins
have common annotated functional properties, we performed
pathway analysis (Tables S5 and S6). As an example, the CDK5
signaling pathway, was found to be significantly enriched
(p=0.00009) for proteins identified only in the pooled CFS
Figure 2. Comparative analysis of individual CFS and nPTLS CSF proteomes. A) Unsupervised hierarchical clustering of 59 proteins (see
Table S3) that are differentially abundant as determined by ANOVA (p,0.01) clearly separates these two disease states with the exception of one
nPTLS sample clustering with CFS patient samples. B) Principal Component Analysis (PCA) of CFS and nPTLS samples demonstrates that the CSF
proteomes, and by extension of the CNS status, differ between CFS and nPTLS.
doi:10.1371/journal.pone.0017287.g002
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[30] and Alzheimer’s diseases [31].
Example of proteins in common and decreased in
abundance in the two disease conditions, compared to
normal, but at different levels. In certain cases, proteins were
found to be decreased in both CFS and nPTLS compared to
healthy normal controls. However, quantitative distinguishing
differences could still be found between the two conditions. A
specific example relates to networks relevant to neurological
function such as axonal guidance (Figures S2A and B), where the
proteins in CFS were further decreased relative to nPTLS. These
findings highlight quantifiable differences between CFS and nPTLS
that may be found, with respect to certain proteins such as those
that are known to effect the dynamic changes in CNS cellular
architecture, such as axon, neurite, and dendritic spine growth and
organization.
Discussion
Our results support the concept that CFS and nPTLS are
distinguishable disorders with distinct CSF proteomes, where one
can be separated from the other. The results also demonstrate that
each condition has a multitude of candidate diagnostic biomarkers
for future validation and optimization studies. The discovery of
many of the same proteins in each proteome is important because
it allows comparative pathway analysis, so that useful hypotheses
of pathogenesis can be formulated and tested.
Our results represent the most comprehensive analysis of the
whole CSF proteome to date for both CFS and nPTLS. These two
disorders have similar symptoms that have created diagnostic
dilemmas. It has been speculated that one (nPTLS) is a subset of
the other, but our results do not support that notion. Our findings
alone do not describe why CFS or nPTLS occur, but are provided
to illustrate that CSF proteome analysis may provide important
and meaningful insights into the biological processes modulated as
a function of disease and facilitate the identification of protein
candidates for further investigation. Analytical strategies need to
be developed for application to those proteins and their pathways
that may not have been described yet. Nevertheless, in toto, these
results are encouraging because there is an abundance of data now
that can be analyzed with existing tools and future methods to
develop hypotheses on pathogenesis [9,32].
We regard the proteins that were identified only in one group or
differentially abundant between groups, as possible or candidate
biomarkers that can be subjected to further analysis in validation
and verification studies. The clinical significance of the proteins
identified in each pooled sample is difficult to determine in the
current discovery phase. As with most technologic methods, we
expect multiple replicate analyses of the highly fractionated
samples would result in a reduction of the number of seemingly
unique proteins identified for each disease group [33].
An important strategy that can be used post-discovery towards
validation, is the use of targeted approaches that are either MS-
based, immuno-based, or a combination of these approaches
[12,34]. One approach, selected reaction monitoring (SRM) MS,
allows for much higher sensitivity and specificity, more accurate
quantification, and much higher throughput to be achieved for
simultaneously measuring many biomarker candidates in large
clinical cohorts [35–37]. This approach also compensates for any
theoretical over-representation of proteins in pooled samples by a
single or small number of individuals. This is a strategy that we
plan to use not only for these diseases, but in the investigation of
other diseases with neuropsychiatric features. SRM-MS analysis
will permit us to directly use small-sized samples, such as the
individual CSF samples, enable verification of marker candidates
that currently do not have available antibodies (hence not
amenable to conventional analyses such as ELISA or Western
blots), and provide robust statistical analyses on individual
candidate markers or combinations of them to determine which
would make the best biomarker(s) for a particular disease
condition. Immunobased assays such as ELISA or Western blots
may also be used for targeted approaches, but will likely have more
utility during a clinical validation phase where much larger sample
cohorts are used. Some may choose to apply these methods for
additional orthogonal confirmation of a result. However, its
greater value may lie in its widespread use as a common diagnostic
platform. Regardless of the method chosen, identification of
diagnostic CSF biomarkers may be the necessary prelude to a
search for the same markers in the highly complex blood, because
it permits targeted searches for markers that might otherwise be
obscured or have uncertain relevance.
With respect to biomarkers, we believe our proteomic strategy
[10], that did not require prior knowledge of which proteins might
be present in the CSF, will accelerate the transition from a
discovery phase of candidate biomarkers, as described in this
study, to full validation for clinical application. We and others
have cited important elements that should be considered when an
assay or biomarker is being developed for preliminary or full
validation [38–40].
Distinguishing CFS and nPTLS will have etiologic implications
which could lead to novel diagnostics and therapeutic interven-
tions. On a broader level the strategy we employed may prove
useful in providing investigative foundations in other poorly
understood neurological conditions.
Supporting Information
Figure S1 Illustrative example of pathway analysis with
respect to complement pathways. Protein network and
pathway analysis was performed employing Ingenuity Pathways
Analysis tools (v8.6- www.ingenuity.com). A) Proteins that
participate in complement signaling were significantly enriched
(p = 6610
220) in the CSF proteomes for pooled disease-specific
samples. A comparison of protein abundance determined by
spectral counts reveals difference between disease states and
normal healthy control CSF. Proteins with an increased
abundance are colored red and those that decrease in abundance
relative to normal healthy control are colored green. B) Proteins
annotated as participating in complement that were detected in
individual patient analysis are shown the heatmap. Protein
abundances measured by ion intensity transformed to Z scores
clearly show differences between CFS and nPTLS patients.
C) Receiver operator characteristic (ROC) curves demonstrate
the discriminating power of the select set of proteins that were
detected as having statistical differences by ANOVA (p,0.05) in
abundance in the analysis of individual patient samples.
(TIF)
Figure S2 Illustrative example of pathway analysis with
respect to axonal guidance pathways. Protein network and
pathway analysis were performed employing Ingenuity Pathways
Analysis tools (v8.6- www.ingenuity.com). A) Proteins that
associated with axonal guidance and signaling were significantly
enriched (p=6610
220) in the CSF proteomes for all pooled
samples. A comparison of protein abundances determined by
spectral counts revealed differences between disease states and
normal healthy control CSF. Proteins with an increased
abundance are colored red and proteins with decreased abun-
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PLoS ONE | www.plosone.org 6 February 2011 | Volume 6 | Issue 2 | e17287dance relative to normal/controls are colored green. B) Normal-
ized protein abundance clearly differs between CFS and nPTLS
patients. C) Receiver operator characteristic (ROC) curves
demonstrate the discriminating power of the select set of proteins
that were detected in individual CSF samples as well as in the
pooled proteome.
(TIF)
Table S1 Proteins identified in normal, CFS, and nPTLS pooled
samples.
(PDF)
Table S2 Proteins (n=474) identified in the analysis of non-
fractionated and immunodepleted individual patient samples.
(PDF)
Table S3 Proteins (n=59) that were quantified and determined
to be significantly different in abundance by ANOVA (p # 0.01)
when comparing CFS from nPTLS subject samples and allow for
separation of these two syndromes when performing unsupervised
hierarchical cluster analysis.
(PDF)
Table S4 Pathway enrichment determination using Ingenuity
pathways analysis tools for proteins present in nPTLS and CFS
proteomes. Analysis of proteins detected in the highly fractionated,
immunodepleted, pooled CSF samples led to the identification of
pathways that are significantly enriched (p # 0.05) by the proteins
from the CSF proteomes.
(PDF)
Table S5 Pathways significantly enriched by proteins identified
only in the pooled sample proteome for nPTLS patients.
(PDF)
Table S6 Pathways significantly enriched by proteins identified
only in the pooled sample proteome for CFS patients.
(PDF)
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